Hilmabiocare Cabergoline 0.25mg/10tabs

Original price was: £45.00.Current price is: £25.00.

Cabergoline tablets are indicated for the treatment of hyperprolactinemic disorders, either idiopathic or due to pituitary adenomas, specifically:
■ Lactation suppression
■ Hyperprolactinemia
■ Adjunctive therapy of prolactin-producing pituitary gland tumors (prolactinomas);
■ Monotherapy of Parkinson’s disease in the early phase;
■ Combination therapy, together with levodopa and a decarboxylase inhibitor such as carbidopa, in progressive-phase Parkinson’s disease;
■ In some cases also: ablactation and dysfunctions associated with hyperprolactinemia (amenorrhea, oligomenorrhea, anovulation, nonpuerperal mastitis and galactorrhea);
■ Treatment of uterine fibroids.
■ Adjunctive therapy of acromegaly, cabergoline has low efficacy in suppressing growth hormone levels and is highly efficient in suppressing hyperprolactinemia that is present in 20-30% of acromegaly cases.

The recommended dosage of Cabergoline tablets for initiation of therapy is 0.25 mg twice a week. Dosage may be increased by 0.25 mg twice weekly up to a dosage of 1 mg twice a week according to the patient’s serum prolactin level.

Before initiating treatment, cardiovascular evaluation should be performed and echocardiography should be considered to assess for valvular disease.

Dosage increases should not occur more rapidly than every 4 weeks, so that the physician can assess the patient’s response to each dosage level. If the patient does not respond adequately, and no additional benefit is observed with higher doses, the lowest dose that achieved maximal response should be used and other therapeutic approaches considered.

Patients receiving long term treatment with Cabergoline should undergo periodic assessment of their cardiac status and echocardiography should be considered.

After a normal serum prolactin level has been maintained for 6 months, Cabergoline may be discontinued, with periodic monitoring of the serum prolactin level to determine whether or when treatment with Cabergoline should be reinstituted. The durability of efficacy beyond 24 months of therapy with Cabergoline has not been established.

Out of stock

SKU: hilmabiocare-cabergoline-250-cabaser Categories: , ,



Company: Hilma Biocare
Active Half-life (Hours): 62-70h
Group: Dopamine receptor agonists
Subgroup: Oral/tablets
Dosage: 0.25 mg/tab
Application (Men): 0.50mg weekly
Product pack: 10 tab.
Content (active): Cabergoline
Retains water: None
Aromatization: None

Product Description

Cabergoline is a dopaminergic derivative of ergoline and is characterized by a pronounced and long-lasting prolactin-lowering effect. Cabergoline affects the body by direct stimulation of D2-dopamine receptors on lactotroph cells in the pituitary gland. In bodybuilding, the drug is used to lower prolactin levels and eliminate the unwanted side effects of the anabolic supplement.


With the help of Cabergoline athletes can reduce adverse reactions attributed to anabolic steroid use, including gynecomastia, water retention and high prolactin level. Additionally, it boosts sex drive, erection and recovery.


The most common side effects attributed to Cabergoline are headache, dizziness, nausea, sleepiness, emotional distress, and stomach pains.

Protection code:

How it works:


Hilma Biocare™ takes care of consumers and regularly develops various means of protecting its products, which ensures patient safety and trust to verify our products

Package sizes:

Additional information


Hilma Biocare

There are no reviews yet.

Be the first to review “Hilmabiocare Cabergoline 0.25mg/10tabs”

Your email address will not be published. Required fields are marked *